Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Benzinga01-23

Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:CYTK), noting the company’s catalyst rich one to two years. The M&A speculation ramped up in early 2024 after the company released ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2505705234?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-23 04:43","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2505705234","market":"us","top_or_hot":-1,"title":"Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst","media":"Benzinga","content":"<div>\n<p>Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:CYTK), noting the company’s catalyst rich one to two years.\nThe M&A speculation ramped up in early 2024 after the company released ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cytokinetics-heart-drugs-future-sparks-204350038.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-23 04:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cytokinetics-heart-drugs-future-sparks-204350038.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:CYTK), noting the company’s catalyst rich one to two years.\nThe M&A speculation ramped up in early 2024 after the company released ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cytokinetics-heart-drugs-future-sparks-204350038.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999001440.SGD","symbol_name":"United Global Dividend Equity Fund A SGD Dist","start_time":0,"source_url":"https://finance.yahoo.com/news/cytokinetics-heart-drugs-future-sparks-204350038.html","article_id":"2505705234","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505705234","pubTimestamp":1737578630,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Stifel initiated coverage on Cytokinetics Incorporated , noting the company’s catalyst rich one to two years.The M&A speculation ramped up in early 2024 after the company released SEQUOIA-HCM Phase 3 trial data ofaficamten in December 2023. However, last year,Novartis AG  decided to step back from pursuing theCytokinetics deal.Amgen Inc , AstraZeneca Plc , and Johnson & Johnson  also all popped up as potential suitors, though the stock faded from there as a deal never materialized.Also Read: Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study. Cytokinetics has fallen out of favor with investors after a turbulent start to 2024, marked by a controversial Royalty Pharma Plc  deal and no mergers or acquisitions.Stifel has initiated coverage with a Buy rating and a price forecast of $80. However, the outlook appears promising, with its valuation adjusted and several catalysts expected over the next 12+ months.Stifel analyst James Cond","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","QLD":"纳指两倍做多ETF","NVIW.SI":"NVDA 3xLongSG261006","BK4578":"CAR-T","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","BK4559":"巴菲特持仓","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","AZN":"阿斯利康","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","USJW.SI":"ALPHAB 3xLongSG261006","TSYW.SI":"TESLA 3xLongSG261006","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0237698245.USD":"富达环球地产基金A","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC",".IXIC":"NASDAQ Composite","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","USAW.SI":"AMZN 3xLongSG261006","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","QID":"纳指两倍做空ETF","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","RPRX":"Royalty Pharma plc","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","BMY":"施贵宝","TQQQ":"纳指三倍做多ETF","NVS":"诺华","CYTK":"Cytokinetics","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","JNJ":"强生","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","AMGN":"安进","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4534":"瑞士信贷持仓","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","PSQ":"纳指反向ETF","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","SQQQ":"纳指三倍做空ETF"},"translate_title":"分析师：尽管存在并购障碍和特许权使用费交易担忧，但Cytokinetics心脏药物的未来仍引发乐观情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1,"NVS":1,"JNJ":1,"RPRX":1,"CYTK":1,"BMY":1,"AZN":1,".IXIC":0.9,"PSQ":0.6,"NVIW.SI":0.6,"USJW.SI":0.6,"TQQQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"USAW.SI":0.6,"TSYW.SI":0.6,"MNQmain":0.6,"NQmain":0.6},"content_text":"Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:CYTK), noting the company’s catalyst rich one to two years.\nThe M&A speculation ramped up in early 2024 after the company released SEQUOIA-HCM Phase 3 trial data of aficamten in December 2023. However, last year, Novartis AG (NYSE:NVS) decided to step back from pursuing the Cytokinetics deal.\nAmgen Inc (NASDAQ:AMGN), AstraZeneca Plc (NASDAQ:AZN), and Johnson & Johnson (NYSE:JNJ) also all popped up as potential suitors, though the stock faded from there as a deal never materialized.\nAlso Read: Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study\nCytokinetics has fallen out of favor with investors after a turbulent start to 2024, marked by a controversial Royalty Pharma Plc (NASDAQ:RPRX) deal and no mergers or acquisitions.\nInvestors poorly received the structure of the Royalty Pharma deal at the time, and it continues to be a concern for many even today.\nStifel has initiated coverage with a Buy rating and a price forecast of $80. However, the outlook appears promising, with its valuation adjusted and several catalysts expected over the next 12+ months.\nStifel analyst James Condulis writes Cytokinetics’ aficamten is an exceptional drug as it sets a strong competitive standard for a multi-billion-dollar obstructive hypertrophic cardiomyopathy (oHCM) market.\nAs the rollout of Bristol Myers Squibb Co’s (NYSE:BMY) Camzyos mavacamten continues, some concerns remain about its potential in treating obstructive hypertrophic cardiomyopathy (oHCM).\nWhile the initial launch is not seen as a negative sign for mavacamten’s potential, its Risk Evaluation and Mitigation Strategy (REMS) is a barrier to fully unlocking the market.\nCytokinetics appears well-positioned to capitalize on Bristol Myers’ groundwork with its second-to-market drug, aficamten, which is expected to have a best-in-class profile. There is a strong case for aficamten to secure a differentiated REMS, potentially including six-month echocardiograms (Q6M echos) as a standard.\nUnder conservative assumptions, aficamten could drive the U.S. oHCM market to approximately $3 billion.\nLooking ahead to 2025 and 2026, Phase 3 nHCM data and early findings for HFpEF could present new opportunities. Although mergers and acquisitions are not a key focus, potential strategic interest could bring unexpected benefits.\nPrice Action: CYTK stock is up 3.45% at $47.40 at last check Wednesday.\nRead Next:\n\nHalliburton Faces Mixed Q4 With North American Weakness, But Global Gains And Cash Flow Bolster Optimism\n\nLatest Ratings for CYTK\n\n\n\nDate\nFirm\nAction\nFrom\nTo\n\n\n\n\nDec 2021\nOppenheimer\nInitiates Coverage On\n\nOutperform\n\n\nDec 2021\nHC Wainwright & Co.\nMaintains\n\nBuy\n\n\nDec 2021\nJP Morgan\nInitiates Coverage On\n\nOverweight\n\n\n\n View More Analyst Ratings for CYTK \n View the Latest Analyst Ratings \nUNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.\nGet the latest stock analysis from Benzinga?\n\nCYTOKINETICS (CYTK): Free Stock Analysis Report\n\nThis article Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst originally appeared on Benzinga.com\n© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2505705234"}